Cbp/p300 degrader (Cullgen)

N/A

Report date: 2025/03/19 08:59:40
NME

Base Information

Drug NameCbp/p300 degrader (Cullgen)
Drug Alias Namethalidomide-based heterobifunctional Cbp/p300 degrader (Cullgen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp300-CBP transcription factors inhibitors
Targetsp300-CBP transcription factors
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCullgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesCullgen Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A